Clinical Trial Update: A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Study of CERC-301 in the Adjunctive Treatment of Subjects With Severe Depression and Recent Active Suicidal Ideation Despite Antidepressant Treatment [Phase 2]

View source ↗

Summary

Phase 2 randomized trial evaluating CERC-301 as adjunctive treatment for severe depression with active suicidal ideation despite antidepressants; completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• CERC-301

Snippet

Sponsor: Avalo Therapeutics, Inc. | Conditions: Major Depressive Disorder | Phase 2 | Status: COMPLETED